Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling

Objective. Increased monocytes, particularly the inflammatory subset, are associated with accelerated atherosclerosis in diabetes through thus far incompletely defined mechanisms. The present study tested the hypothesis that advanced glycation end products (AGEs) promote bone marrow monocytes to pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Xian Jin, Liang Liu, Yaping Zhang, Yin Xiang, Guizhi Yin, Yi Lu, Ludong Shi, Jian Dong, Chengxing Shen
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2018/2527406
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560873337520128
author Xian Jin
Liang Liu
Yaping Zhang
Yin Xiang
Guizhi Yin
Yi Lu
Ludong Shi
Jian Dong
Chengxing Shen
author_facet Xian Jin
Liang Liu
Yaping Zhang
Yin Xiang
Guizhi Yin
Yi Lu
Ludong Shi
Jian Dong
Chengxing Shen
author_sort Xian Jin
collection DOAJ
description Objective. Increased monocytes, particularly the inflammatory subset, are associated with accelerated atherosclerosis in diabetes through thus far incompletely defined mechanisms. The present study tested the hypothesis that advanced glycation end products (AGEs) promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype. Methods and Results. In vivo, AGEs (25 mg/kg i.p. for 7 days) increased proportions of CD115+ monocytes and the inflammatory subset, the CD115+Ly6Chigh cells, in murine bone marrow (flow cytometry analysis (FCM)), and enhanced gene expression of proinflammatory cytokines (IL-1β and TNF-α) but only slightly upregulated mRNA expression of anti-inflammatory cytokine (IL-10) (real-time PCR) in monocytes. In vitro, when the monocytes were treated with different dosages of AGEs (50, 150, and 300 μg/mL), we found that proliferation (CCK8) but not apoptosis (FCM) of the monocytes was induced; the mRNA expressions of proinflammatory cytokines (IL-1β and TNF-α) and GM-CSF were upregulated in a dose-dependent manner while mRNA levels of IL-10 and M-CSF were changed much less in monocytes (real-time PCR). Furthermore, AGEs (300 μg/mL) significantly enhanced the expression of Ki67 in monocytes (immunofluorescence staining (IF)), and this dose of AGEs markedly increased secretion of GM-CSF but not that of M-CSF (ELISA). For a pathway study, the monocytes were stimulated by 300 μg/mL AGEs for different periods of time (0, 15, 30, and 120 min) and the activation of the MAPK pathway was tested (FCM); the results showed the p38 and ERK pathways were activated but not JNK signaling. Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF). Conclusions. AGEs promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype through p38 and ERK activation.
format Article
id doaj-art-670cf5a30c284343af2615758c6cb308
institution Kabale University
issn 2314-6745
2314-6753
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-670cf5a30c284343af2615758c6cb3082025-02-03T01:26:29ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/25274062527406Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK SignalingXian Jin0Liang Liu1Yaping Zhang2Yin Xiang3Guizhi Yin4Yi Lu5Ludong Shi6Jian Dong7Chengxing Shen8Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, ChinaDepartment of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, ChinaDepartment of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, ChinaDepartment of Cardiology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Cardiology, Minhang Hospital, Fudan University, Shanghai, ChinaDepartment of Cardiology, Minhang Hospital, Fudan University, Shanghai, ChinaDepartment of Cardiology, Minhang Hospital, Fudan University, Shanghai, ChinaDepartment of Cardiology, Minhang Hospital, Fudan University, Shanghai, ChinaDepartment of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, ChinaObjective. Increased monocytes, particularly the inflammatory subset, are associated with accelerated atherosclerosis in diabetes through thus far incompletely defined mechanisms. The present study tested the hypothesis that advanced glycation end products (AGEs) promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype. Methods and Results. In vivo, AGEs (25 mg/kg i.p. for 7 days) increased proportions of CD115+ monocytes and the inflammatory subset, the CD115+Ly6Chigh cells, in murine bone marrow (flow cytometry analysis (FCM)), and enhanced gene expression of proinflammatory cytokines (IL-1β and TNF-α) but only slightly upregulated mRNA expression of anti-inflammatory cytokine (IL-10) (real-time PCR) in monocytes. In vitro, when the monocytes were treated with different dosages of AGEs (50, 150, and 300 μg/mL), we found that proliferation (CCK8) but not apoptosis (FCM) of the monocytes was induced; the mRNA expressions of proinflammatory cytokines (IL-1β and TNF-α) and GM-CSF were upregulated in a dose-dependent manner while mRNA levels of IL-10 and M-CSF were changed much less in monocytes (real-time PCR). Furthermore, AGEs (300 μg/mL) significantly enhanced the expression of Ki67 in monocytes (immunofluorescence staining (IF)), and this dose of AGEs markedly increased secretion of GM-CSF but not that of M-CSF (ELISA). For a pathway study, the monocytes were stimulated by 300 μg/mL AGEs for different periods of time (0, 15, 30, and 120 min) and the activation of the MAPK pathway was tested (FCM); the results showed the p38 and ERK pathways were activated but not JNK signaling. Pretreatment with an inhibitor of p38 (SB203580) or ERK (U0126) attenuated AGE-induced gene expression of proinflammatory cytokines and GM-CSF (real-time PCR), as well as reversing AGE-induced Ki67 expression (IF). Conclusions. AGEs promote bone marrow monocytes to proliferate and drive them into an inflammatory phenotype through p38 and ERK activation.http://dx.doi.org/10.1155/2018/2527406
spellingShingle Xian Jin
Liang Liu
Yaping Zhang
Yin Xiang
Guizhi Yin
Yi Lu
Ludong Shi
Jian Dong
Chengxing Shen
Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
Journal of Diabetes Research
title Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
title_full Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
title_fullStr Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
title_full_unstemmed Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
title_short Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling
title_sort advanced glycation end products enhance murine monocyte proliferation in bone marrow and prime them into an inflammatory phenotype through mapk signaling
url http://dx.doi.org/10.1155/2018/2527406
work_keys_str_mv AT xianjin advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT liangliu advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT yapingzhang advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT yinxiang advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT guizhiyin advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT yilu advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT ludongshi advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT jiandong advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling
AT chengxingshen advancedglycationendproductsenhancemurinemonocyteproliferationinbonemarrowandprimethemintoaninflammatoryphenotypethroughmapksignaling